Business Context and Reporting Period
This Form 8-K was filed by Recursion Pharmaceuticals, Inc. on June 21, 2022, reporting an event that occurred on June 20, 2022. The company is a Delaware corporation with its principal executive offices in Salt Lake City, Utah, and its Class A common stock trades on the Nasdaq Global Select Market under the symbol RXRX. The registrant is classified as an emerging growth company.
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding a specific corporate event and does not contain financial statements. Consequently, there are no reported values for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
The material change reported is the initiation of a new clinical trial:
- Event: Initiation of the Phase 2/3 POPLAR-NF2 trial.
- Indication: Treatment of NF2-mutated meningiomas.
- Announcement Date: June 20, 2022.
Guidance, Outlook, and Risks
The filing references a press release (Exhibit 99.1) detailing the trial initiation but does not provide specific financial guidance, management commentary on future performance, or a discussion of risks and contingencies within the text of the 8-K itself. No unusual items or financial contingencies are disclosed in this report.
Investor Verification Checklist
- Verify the full details of the POPLAR-NF2 trial design and enrollment criteria in the attached press release (Exhibit 99.1).
- Review the company's most recent 10-Q or 10-K for current financial health, cash runway, and liquidity status, as this 8-K contains no financial data.
- Monitor future filings for updates on the trial's progress and any potential impact on the company's capital requirements.